TY - JOUR
T1 - A scoring tool to predict mortality and dependency after cerebral venous thrombosis
AU - Lindgren, Erik
AU - Krzywicka, Katarzyna
AU - de Winter, Maria A.
AU - Sánchez Van Kammen, Mayte
AU - Heldner, Mirjam R.
AU - Hiltunen, Sini
AU - Aguiar de Sousa, Diana
AU - Mansour, Maryam
AU - Canhão, Patrícia
AU - Ekizoğlu, Esme
AU - Rodrigues, Miguel
AU - Martins Silva, Elisa
AU - Garcia-Esperon, Carlos
AU - Arnao, Valentina
AU - Aridon, Paolo
AU - Simaan, Naaem Moin
AU - Silvis, Suzanne M.
AU - Zuurbier, Susanna M.
AU - Scutelnic, Adrian
AU - Sezgin, Mine
AU - Alasheev, Andrey Marisovich
AU - Smolkin, Andrey
AU - Guisado-Alonso, Daniel
AU - Yesilot, Nilufer
AU - Barboza, Miguel
AU - Ghiasian, Masoud
AU - Leker, Ronen R.
AU - Arauz, Antonio
AU - Arnold, Marcel
AU - Putaala, Jukka
AU - Tatlisumak, Turgut
AU - Coutinho, Jonathan M.
AU - Jood, Katarina
N1 - Publisher Copyright:
© 2023 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
PY - 2023/8
Y1 - 2023/8
N2 - Background and purpose: A prognostic score was developed to predict dependency and death after cerebral venous thrombosis (CVT) to identify patients for targeted therapy in future clinical trials. Methods: Data from the International CVT Consortium were used. Patients with pre-existent functional dependency were excluded. Logistic regression was used to predict poor outcome (modified Rankin Scale score 3–6) at 6 months and Cox regression to predict 30-day and 1-year all-cause mortality. Potential predictors derived from previous studies were selected with backward stepwise selection. Coefficients were shrunk using ridge regression to adjust for optimism in internal validation. Results: Of 1454 patients with CVT, the cumulative number of deaths was 44 (3%) and 70 (5%) for 30 days and 1 year, respectively. Of 1126 patients evaluated regarding functional outcome, 137 (12%) were dependent or dead at 6 months. From the retained predictors for both models, the SI2NCAL2C score was derived utilizing the following components: absence of female-sex-specific risk factor, intracerebral hemorrhage, infection of the central nervous system, neurological focal deficits, coma, age, lower level of hemoglobin (g/l), higher level of glucose (mmol/l) at admission, and cancer. C-statistics were 0.80 (95% confidence interval [CI] 0.75–0.84), 0.84 (95% CI 0.80–0.88) and 0.84 (95% CI 0.80–0.88) for the poor outcome, 30-day and 1-year mortality model, respectively. Calibration plots indicated a good model fit between predicted and observed values. The SI2NCAL2C score calculator is freely available at www.cerebralvenousthrombosis.com. Conclusions: The SI2NCAL2C score shows adequate performance for estimating individual risk of mortality and dependency after CVT but external validation of the score is warranted.
AB - Background and purpose: A prognostic score was developed to predict dependency and death after cerebral venous thrombosis (CVT) to identify patients for targeted therapy in future clinical trials. Methods: Data from the International CVT Consortium were used. Patients with pre-existent functional dependency were excluded. Logistic regression was used to predict poor outcome (modified Rankin Scale score 3–6) at 6 months and Cox regression to predict 30-day and 1-year all-cause mortality. Potential predictors derived from previous studies were selected with backward stepwise selection. Coefficients were shrunk using ridge regression to adjust for optimism in internal validation. Results: Of 1454 patients with CVT, the cumulative number of deaths was 44 (3%) and 70 (5%) for 30 days and 1 year, respectively. Of 1126 patients evaluated regarding functional outcome, 137 (12%) were dependent or dead at 6 months. From the retained predictors for both models, the SI2NCAL2C score was derived utilizing the following components: absence of female-sex-specific risk factor, intracerebral hemorrhage, infection of the central nervous system, neurological focal deficits, coma, age, lower level of hemoglobin (g/l), higher level of glucose (mmol/l) at admission, and cancer. C-statistics were 0.80 (95% confidence interval [CI] 0.75–0.84), 0.84 (95% CI 0.80–0.88) and 0.84 (95% CI 0.80–0.88) for the poor outcome, 30-day and 1-year mortality model, respectively. Calibration plots indicated a good model fit between predicted and observed values. The SI2NCAL2C score calculator is freely available at www.cerebralvenousthrombosis.com. Conclusions: The SI2NCAL2C score shows adequate performance for estimating individual risk of mortality and dependency after CVT but external validation of the score is warranted.
KW - cerebral venous thrombosis
KW - dependency
KW - follow-up
KW - mortality
KW - outcome
KW - prognosis
KW - risk score
KW - stroke
UR - http://www.scopus.com/inward/record.url?scp=85160937323&partnerID=8YFLogxK
U2 - 10.1111/ene.15844
DO - 10.1111/ene.15844
M3 - Article
C2 - 37165521
AN - SCOPUS:85160937323
SN - 1351-5101
VL - 30
SP - 2305
EP - 2314
JO - European Journal of Neurology
JF - European Journal of Neurology
IS - 8
ER -